These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

510 related articles for article (PubMed ID: 28754120)

  • 1. Nano-based delivery of RNAi in cancer therapy.
    Xin Y; Huang M; Guo WW; Huang Q; Zhang LZ; Jiang G
    Mol Cancer; 2017 Jul; 16(1):134. PubMed ID: 28754120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanoparticle-siRNA: A potential cancer therapy?
    Young SW; Stenzel M; Yang JL
    Crit Rev Oncol Hematol; 2016 Feb; 98():159-69. PubMed ID: 26597018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imaging-guided delivery of RNAi for anticancer treatment.
    Wang J; Mi P; Lin G; Wáng YX; Liu G; Chen X
    Adv Drug Deliv Rev; 2016 Sep; 104():44-60. PubMed ID: 26805788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanoparticle-based delivery of small interfering RNA: challenges for cancer therapy.
    Miele E; Spinelli GP; Miele E; Di Fabrizio E; Ferretti E; Tomao S; Gulino A
    Int J Nanomedicine; 2012; 7():3637-57. PubMed ID: 22915840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanoparticles as Drug Delivery Systems of RNAi in Cancer Therapy.
    Li D; Gao C; Kuang M; Xu M; Wang B; Luo Y; Teng L; Xie J
    Molecules; 2021 Apr; 26(8):. PubMed ID: 33921892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interfering cancer with polymeric siRNA nanomedicines.
    Tiram G; Scomparin A; Ofek P; Satchi-Fainaro R
    J Biomed Nanotechnol; 2014 Jan; 10(1):50-66. PubMed ID: 24724498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo application of RNA interference: from functional genomics to therapeutics.
    Lu PY; Xie F; Woodle MC
    Adv Genet; 2005; 54():117-42. PubMed ID: 16096010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RNAi-based therapeutics and tumor targeted delivery in cancer.
    Kara G; Calin GA; Ozpolat B
    Adv Drug Deliv Rev; 2022 Mar; 182():114113. PubMed ID: 35063535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RNA interference-based therapy and its delivery systems.
    Chen X; Mangala LS; Rodriguez-Aguayo C; Kong X; Lopez-Berestein G; Sood AK
    Cancer Metastasis Rev; 2018 Mar; 37(1):107-124. PubMed ID: 29243000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Budding Alliance of Nanotechnology in RNA Interference Therapeutics.
    Kumawat A; Dapse P; Kumar N; Mishra DK; Maheshwari R; Bhattacharya P; Tekade RK
    Curr Pharm Des; 2018; 24(23):2632-2643. PubMed ID: 30084328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RNA interference (RNAi)-based plasmonic nanomaterials for cancer diagnosis and therapy.
    Yoon J; Shin M; Lee JY; Lee SN; Choi JH; Choi JW
    J Control Release; 2022 Feb; 342():228-240. PubMed ID: 35016917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RNAi-mediated gene silencing in cancer therapy.
    Yang WQ; Zhang Y
    Expert Opin Biol Ther; 2012 Nov; 12(11):1495-504. PubMed ID: 22849542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An update on RNA interference-mediated gene silencing in cancer therapy.
    Ren YJ; Zhang Y
    Expert Opin Biol Ther; 2014 Nov; 14(11):1581-92. PubMed ID: 25010067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor-targeting multifunctional nanoparticles for siRNA delivery: recent advances in cancer therapy.
    Ku SH; Kim K; Choi K; Kim SH; Kwon IC
    Adv Healthc Mater; 2014 Aug; 3(8):1182-93. PubMed ID: 24577795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Critical issues in delivery of RNAi therapeutics in vivo.
    Rivera S; Yuan F
    Curr Pharm Biotechnol; 2012 Jun; 13(7):1279-91. PubMed ID: 22201583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in siRNA delivery strategies for the treatment of MDR cancer.
    Subhan MA; Attia SA; Torchilin VP
    Life Sci; 2021 Jun; 274():119337. PubMed ID: 33713664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of RNAi technology for targeted therapy--a track of siRNA based agents to RNAi therapeutics.
    Zhou Y; Zhang C; Liang W
    J Control Release; 2014 Nov; 193():270-81. PubMed ID: 24816071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Applicability of RNA interference in cancer therapy: Current status.
    Maduri S
    Indian J Cancer; 2015; 52(1):11-21. PubMed ID: 26837960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic potentials of gene silencing by RNA interference: principles, challenges, and new strategies.
    Deng Y; Wang CC; Choy KW; Du Q; Chen J; Wang Q; Li L; Chung TK; Tang T
    Gene; 2014 Apr; 538(2):217-27. PubMed ID: 24406620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent advances in exosome-based nanovehicles as RNA interference therapeutic carriers.
    Maheshwari R; Tekade M; Gondaliya P; Kalia K; D'Emanuele A; Tekade RK
    Nanomedicine (Lond); 2017 Nov; 12(21):2653-2675. PubMed ID: 28960165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.